Sardeshmukh Sadanand, Deshmukh Vineeta, Kulkarni Arvind, Gujar Shweta, Awalkanthe Vinita, Sardeshmukh Nilambari, Sardeshmukh Bhagyashree, Deshpande Dhananjay, Deshpande Anjali, Chavan Sandeep
Bharatiya Sanskriti Darshan Trust's Integrated Cancer Treatment and Research Centre, Wagholi, Pune, Maharashtra, India.
Bharatiya Sanskriti Darshan Trust's Integrated Cancer Treatment and Research Centre, Wagholi, Pune, Maharashtra, India.
J Ayurveda Integr Med. 2024 Nov-Dec;15(6):100999. doi: 10.1016/j.jaim.2024.100999. Epub 2024 Dec 10.
Ovarian cancer patients with BRCA1 mutation have more susceptibility for secondary breast cancer. In females with BRCA1 mutation, the risk of developing breast carcinoma is 65% and of ovarian cancer is 39%, before 70 years of age. This is a case report of a 74 year old, post-menopausal woman diagnosed with metastatic retroperitoneal lymph node, high-grade papillary adenocarcinoma primary ovary stage IIIA in April 2004 at the age of 48 years. She underwent 3 cycles of neo-adjuvant chemotherapy Inj. Methotrexate and Inj. Carboplatin from June to August 2004 followed by optimum cytoreduction in September 2004. Later she completed 3 more cycles of chemotherapy of the same protocol from October to November 2004. Tab Etoposide was given from December 2004 to October 2006. In May 2006, during oral chemotherapy and with unremarkable radiological findings, the patient chose Ayurvedic treatment in view of immune boosting, and improving quality of life. The patient underwent 11 sets of Panchakarma treatment, almost every year, from December 2007 to September 2019. She was disease-free for 13 years leading a good quality of life with adjunct Ayurvedic treatment. In October 2019, she was diagnosed with Left breast duct carcinoma with ER, PR hormone positive status. Her genetic mutation analysis report at that time revealed BRCA 1 mutation. She underwent Left Modified Radical Mastectomy in October 2019, followed by prophylactic Right Breast Mastectomy and oral hormonal therapy. Now she is living with better quality of life with adjunct Ayurvedic treatment, including Oral Ayurvedic Medicines possessing Rasayana (immunomodulatory) and hepato-protective activity and 12 sets of Panchakarma Chikitsa. In this case of Stage IIIA Ovarian carcinoma and second primary Breast carcinoma with BRCA 1 genetic mutation (HBOC syndrome), a long-term 13 years of disease-free survival, and 20 years of overall survival is achieved with the integration of Ayurvedic treatment and conventional cancer treatment.
携带BRCA1突变的卵巢癌患者患继发性乳腺癌的易感性更高。在携带BRCA1突变的女性中，70岁之前患乳腺癌的风险为65%，患卵巢癌的风险为39%。这是一例74岁绝经后女性的病例报告，该患者于2004年48岁时被诊断为转移性腹膜后淋巴结、原发性卵巢高级别乳头状腺癌IIIA期。她在2004年6月至8月接受了3个周期的新辅助化疗，使用甲氨蝶呤注射液和卡铂注射液，随后于2004年9月进行了最佳肿瘤细胞减灭术。之后，她在2004年10月至11月又完成了3个周期的相同方案化疗。2004年12月至2006年10月给予依托泊苷片。2006年5月，在口服化疗期间且影像学检查无异常发现时，鉴于免疫增强和改善生活质量，患者选择了阿育吠陀疗法。从2007年12月到2019年9月，该患者几乎每年接受11次净化疗法治疗。在辅助阿育吠陀疗法的情况下，她无病生存了13年，生活质量良好。2019年10月，她被诊断为左乳腺导管癌，雌激素受体、孕激素受体激素呈阳性状态。当时她的基因突变分析报告显示存在BRCA 1突变。她于2019年10月接受了左改良根治性乳房切除术，随后进行了预防性右乳房切除术和口服激素治疗。现在，在辅助阿育吠陀疗法的情况下，她生活质量更好，阿育吠陀疗法包括具有rasayana（免疫调节）和肝脏保护活性的口服阿育吠陀药物以及12次净化疗法治疗。在这例IIIA期卵巢癌和伴有BRCA 1基因突变（遗传性乳腺癌卵巢癌综合征）的第二原发性乳腺癌病例中，通过将阿育吠陀疗法与传统癌症治疗相结合，实现了长达13年的无病生存期和20年的总生存期。
